Pharmacokinetics - USMLE Step 1

SECTION 1

Historical Context & Motivation

For centuries, physicians administered drugs with little understanding of how those substances moved through the body, relying instead on observation and empirical adjustment. The emergence of pharmacokinetics as a quantitative discipline transformed drug therapy from an art of trial and error into a science grounded in measurable parameters. By characterizing the time course of drug absorption, distribution, metabolism, and excretion, pharmacokinetics provided the mathematical framework necessary to predict plasma concentrations and design rational dosing regimens. This history is not merely academic—understanding the milestones in pharmacokinetic thought reveals why certain equations, models, and clinical assumptions persist in modern therapeutics and USMLE examinations.

1847 • Buchanan's Early Distribution Studies

Early investigations into how chloroform distributed throughout the blood and tissues laid groundwork for understanding drug disposition, though formal kinetic models were still decades away.

1913 • Michaelis-Menten Enzyme Kinetics

Leonor Michaelis and Maud Menten published their landmark enzyme kinetics equation, which would later be applied to saturable drug metabolism, particularly for drugs like phenytoin and ethanol.

1937 • Teorell's Pharmacokinetic Model

Torsten Teorell published a series of papers proposing mathematical models for drug absorption and distribution—widely considered the birth of modern pharmacokinetics as a quantitative discipline.

1953 • Nelson's Compartmental Analysis

E. Nelson introduced compartmental modeling, formalizing the one- and two-compartment models that remain foundational for calculating volume of distribution, clearance, and half-life in clinical practice.

1970s • Therapeutic Drug Monitoring Era

The widespread availability of immunoassays enabled routine measurement of plasma drug concentrations, making pharmacokinetic calculations clinically actionable for drugs with narrow therapeutic indices such as aminoglycosides, vancomycin, and lithium.

The central question pharmacokinetics addresses is deceptively simple: how does a drug's concentration in the body change over time, and how can we control that change to maintain therapeutic efficacy while avoiding toxicity? Answering this question requires integrating concepts from physiology, biochemistry, and applied mathematics—a synthesis that forms the backbone of rational drug dosing and much of the pharmacology tested on USMLE Step 1.

SECTION 2

Core Principles & Definitions

Pharmacokinetics is often summarized by the acronym ADME—Absorption, Distribution, Metabolism, and Excretion. These four processes collectively determine the concentration of a drug at its site of action over time. While pharmacodynamics asks "what does the drug do to the body?," pharmacokinetics asks "what does the body do to the drug?" Each ADME component is governed by distinct physiological mechanisms and described by specific quantitative parameters that are essential for USMLE preparation.

Absorption

The process by which a drug moves from its site of administration into the systemic circulation. Governed by bioavailability (F), route of administration, and first-pass metabolism. IV drugs have F = 1 by definition.

Distribution

The reversible transfer of drug from blood into tissues. Quantified by the volume of distribution (Vd), which reflects the apparent space a drug occupies. A high Vd indicates extensive tissue binding; a low Vd suggests confinement to plasma.

Metabolism

Enzymatic biotransformation, primarily hepatic, converting lipophilic drugs into more hydrophilic metabolites. Phase I reactions (CYP450 oxidation, reduction, hydrolysis) and Phase II reactions (conjugation) facilitate subsequent renal elimination.

Excretion

Irreversible removal of drug from the body, predominantly via the kidneys (glomerular filtration, tubular secretion) and biliary system. Quantified by clearance (CL), the volume of plasma completely cleared of drug per unit time.

Half-Life (t₁/₂)

The time required for plasma drug concentration to decrease by 50%. Determined by both Vd and CL: t_1/2 = 0.693 × Vd / CL. A drug reaches steady state after approximately 4–5 half-lives of repeated dosing.

✦

KEY TAKEAWAY

Think of ADME like a river system. Absorption is the tributary feeding into the main river (systemic circulation). Distribution is the river branching into side channels and floodplains (tissues). Metabolism is a chemical treatment plant altering the water's composition. Excretion is the outflow to the sea—gone for good. Half-life tells you how quickly the water level drops once you shut off the tributary.

SECTION 3

Visual Explanation — The Plasma Concentration–Time Curve

The plasma concentration–time curve is the single most important visual representation in pharmacokinetics. After oral drug administration, the curve exhibits a characteristic rise during the absorption phase, reaches a peak concentration (C_max) at time T_max, and then declines as elimination predominates. The area under this curve (AUC) reflects overall drug exposure and is directly proportional to the amount of drug that reaches systemic circulation. The diagram below illustrates these relationships along with the therapeutic window—the concentration range between the minimum effective concentration (MEC) and the minimum toxic concentration (MTC).

The cyan curve represents drug concentration over time after oral administration. The peak (C_max) occurs at T_max. The shaded area beneath the curve is the AUC. The yellow band between the MEC and MTC is the therapeutic window.

Several clinically important points emerge from this graph. First, the onset of drug action corresponds to the time the curve crosses the MEC from below, and the duration of action is the interval during which the concentration remains above the MEC. Second, if the curve exceeds the MTC, toxic effects become likely—a principle that underscores why drugs with narrow therapeutic indices (such as warfarin, digoxin, and lithium) require careful dose titration and monitoring. Third, the AUC is the primary measure used in bioequivalence studies comparing generic and brand-name formulations.

SECTION 4

Mathematical Framework

Pharmacokinetic parameters are interconnected by a small set of fundamental equations. Mastering these relationships is essential for USMLE Step 1, where questions frequently require you to predict how changes in one parameter (e.g., renal impairment reducing clearance) will affect others (e.g., half-life, steady-state concentration). The following equations assume first-order kinetics, meaning the rate of elimination is proportional to drug concentration—this applies to the majority of drugs at therapeutic doses.

VOLUME OF DISTRIBUTION

Vd = Amount of drug in body / Plasma drug concentration

Vd = volume of distribution (L or L/kg); relates the total amount of drug in the body to its plasma concentration. A Vd of ~3 L suggests confinement to plasma; ~14 L to extracellular fluid; ~42 L to total body water; and values exceeding 42 L indicate extensive tissue sequestration (e.g., chloroquine Vd ≈ 13,000 L).

CLEARANCE

CL = Rate of elimination / Plasma drug concentration = Vd × k_e

CL = clearance (L/hr or mL/min); k_e = elimination rate constant (hr⁻¹). Total body clearance is the sum of renal clearance and hepatic clearance (plus any minor routes).

HALF-LIFE

t₁/₂ = (0.693 × Vd) / CL

t_1/2 = elimination half-life; 0.693 = ln(2). This equation reveals that half-life is directly proportional to Vd and inversely proportional to CL. A larger 'tank' (Vd) or a slower 'drain' (CL) means it takes longer to halve the concentration.

STEADY-STATE CONCENTRATION

Css = (F × Dose) / (CL × τ) [for repeated oral dosing]

C_ss = average steady-state concentration; F = bioavailability (fraction absorbed); τ = dosing interval. Steady state is reached after ~4–5 half-lives. Doubling the dose doubles C_ss; only changing the dosing interval or using a loading dose alters how quickly steady state is achieved.

LOADING DOSE

Loading Dose = (Cp × Vd) / F

C_p = desired target plasma concentration. The loading dose bypasses the 4–5 half-life wait for steady state, immediately achieving therapeutic concentrations. Loading dose depends on Vd, not CL.

💡

USMLE High-Yield Distinction

A common board question tests whether dose adjustments depend on Vd or CL. Remember: loading dose depends on Vd (to fill the 'tank'), while maintenance dose depends on CL (to match the 'drain'). In renal failure, CL decreases → lower maintenance dose. Vd is usually unaffected, so loading dose remains the same.

SECTION 5

First-Order vs. Zero-Order Kinetics

Most drugs follow first-order elimination kinetics at therapeutic concentrations: a constant fraction of the drug is eliminated per unit time. This produces an exponential decay curve and a constant half-life. However, when metabolic enzymes become saturated—as occurs with phenytoin, ethanol, and aspirin at toxic doses—elimination switches to zero-order kinetics: a constant amount is eliminated per unit time, regardless of concentration. This distinction is clinically critical because small dose increases in zero-order drugs can cause disproportionately large rises in plasma concentration, rapidly reaching toxic levels.

Left: first-order kinetics shows exponential decline with a constant half-life. Right: zero-order kinetics shows linear decline at a constant rate. Remember the mnemonic PEA for zero-order drugs: Phenytoin, Ethanol, Aspirin (at high doses).

Feature	First-Order	Zero-Order
Rate of elimination	Proportional to concentration (constant fraction/time)	Constant amount per unit time (independent of concentration)
Half-life	Constant — does not change with concentration	Not constant — increases as concentration increases
Plot (linear scale)	Exponential (curvilinear) decay	Straight line (linear) decay
Plot (log scale)	Straight line (slope = −k_e/2.303)	Curvilinear
Clinical examples	Most drugs at therapeutic doses	Phenytoin, ethanol, aspirin (at saturation)
Dose–response risk	Predictable; doubling dose doubles C_ss	Dangerous; small dose increase → disproportionate C_ss rise

Comparison of first-order and zero-order elimination kinetics

SECTION 6

Worked Example — Calculating Maintenance Dose and Loading Dose

A 70 kg patient requires an IV infusion of Drug X. The target steady-state plasma concentration (C_ss) is 15 mg/L. Drug X has a volume of distribution (Vd) of 50 L, a clearance (CL) of 5 L/hr, and is given intravenously (F = 1). Calculate the maintenance infusion rate, the loading dose, and the half-life.

Drug X Dosing Calculations

1
Step 1 — Calculate the half-life

Using the half-life equation: t_1/2 = (0.693 × Vd) / CL = (0.693 × 50 L) / 5 L/hr = 34.65 / 5

t₁/₂ ≈ 6.93 hours
2
Step 2 — Determine time to reach steady state

Steady state is reached after approximately 4–5 half-lives. Time to steady state = 5 × 6.93 hr

≈ 34.65 hours (about 1.5 days)
3
Step 3 — Calculate the maintenance infusion rate

At steady state for an IV infusion: C_ss = Infusion Rate / CL. Therefore, Infusion Rate = C_ss × CL = 15 mg/L × 5 L/hr

Maintenance infusion rate = 75 mg/hr
4
Step 4 — Calculate the loading dose

To immediately achieve the target concentration without waiting 34.65 hours: Loading Dose = C_p × Vd / F = 15 mg/L × 50 L / 1

Loading Dose = 750 mg
5
Step 5 — Clinical interpretation

Administering a 750 mg bolus achieves the target of 15 mg/L immediately. The continuous infusion of 75 mg/hr then maintains this level by replacing exactly the amount eliminated per hour (CL × C_ss = 5 × 15 = 75 mg/hr). Notice that the loading dose depends on Vd while the maintenance dose depends on CL—a critical distinction for renal and hepatic dose adjustments.

Loading dose → Vd; Maintenance dose → CL

SECTION 7

Clinical Factors Affecting Pharmacokinetics

Real-world pharmacokinetics is rarely as clean as textbook calculations because patient-specific factors introduce significant variability. Understanding how pathophysiological states, drug interactions, and patient demographics alter ADME parameters is essential both for clinical practice and for Step 1 questions that present clinical vignettes requiring dose modifications.

Factor	PK Parameter(s) Affected	Clinical Consequence
Renal impairment	↓ CL (renal); ↑ t_1/2	Reduce maintenance dose of renally cleared drugs (aminoglycosides, vancomycin, lithium); loading dose usually unchanged
Hepatic failure (cirrhosis)	↓ CL (hepatic); ↓ albumin → altered Vd; ↓ first-pass metabolism → ↑ F	Increased bioavailability of high-extraction drugs; prolonged half-life; increased free fraction of protein-bound drugs
Heart failure	↓ CL (hepatic and renal due to ↓ perfusion); variable Vd	Reduced clearance of lidocaine, theophylline; may need lower maintenance doses
CYP450 enzyme inducers (rifampin, phenobarbital, carbamazepine)	↑ CL (hepatic); ↓ t_1/2; ↓ C_ss	Sub-therapeutic drug levels; may need to increase maintenance dose (e.g., rifampin reducing warfarin efficacy)
CYP450 enzyme inhibitors (ketoconazole, erythromycin, grapefruit juice)	↓ CL (hepatic); ↑ t_1/2; ↑ C_ss	Drug toxicity risk; may need to decrease dose (e.g., erythromycin + theophylline → theophylline toxicity)
Age (neonates / elderly)	Neonates: immature CYP450, ↓ renal function, ↑ body water. Elderly: ↓ hepatic mass, ↓ GFR, altered body composition	Both populations require careful dose reduction; neonates have prolonged drug half-lives; elderly at risk for drug accumulation
Protein binding displacement	↑ free fraction → transiently ↑ Vd, ↑ CL; but free C_ss may remain unchanged at new steady state	Clinically significant only for highly protein-bound, narrow therapeutic index drugs (warfarin, phenytoin); interpret total levels cautiously

Common clinical factors altering pharmacokinetic parameters

✦

KEY TAKEAWAY

Think of pharmacokinetic variability like variations in plumbing. A clogged drain (renal failure) means water (drug) backs up in the tank; you need to reduce the inflow (maintenance dose) to prevent overflow (toxicity). A larger drain (CYP induction) means water exits faster; you need more inflow to maintain the same level. The size of the tank (Vd) determines how much you need to initially fill it (loading dose), regardless of the drain size.

SECTION 8

Connection to Advanced Pharmacokinetic Theory

While USMLE Step 1 primarily tests one-compartment, first-order pharmacokinetics, an awareness of more sophisticated models provides deeper understanding and occasionally surfaces in challenging board questions. The two-compartment model divides the body into a central compartment (blood and highly perfused organs) and a peripheral compartment (muscle, fat, bone). Drug concentration in this model shows a biphasic decline: a rapid distribution phase (α phase) followed by a slower elimination phase (β phase). This is clinically relevant for drugs like thiopental, whose rapid redistribution from brain to muscle and fat terminates its CNS effects before elimination begins.

Concept	Basic (Step 1 Core)	Advanced Extension
Compartment model	One-compartment: drug distributes instantaneously; single exponential decline	Two- or multi-compartment: distribution and elimination phases; biexponential or multiexponential decline
Elimination kinetics	First-order (constant fraction) vs. zero-order (constant amount)	Michaelis-Menten kinetics: mixed order at intermediate concentrations; V_max and K_m parameters for saturable enzymes
Bioavailability	F = AUC_oral / AUC_IV	Extraction ratio (E): F = 1 − E for first-pass. High-extraction drugs (morphine, lidocaine, propranolol) have highly variable oral bioavailability
Clearance	CL = Vd × k_e; total = renal + hepatic	Hepatic clearance = Q × E (where Q = hepatic blood flow). Flow-limited vs. capacity-limited elimination; nonlinear pharmacokinetics (phenytoin)
Population PK	Dosing based on weight, age, renal function	Nonlinear mixed-effects modeling (NONMEM); Bayesian dose individualization used in precision medicine

Basic vs. advanced pharmacokinetic concepts

For Step 1 preparation, focus on mastering the one-compartment model, the core equations, and the clinical scenarios that alter pharmacokinetic parameters. The advanced concepts listed above will become increasingly important during clerkships and Step 2, particularly when managing patients on drugs like vancomycin (which follows two-compartment kinetics) or phenytoin (which exhibits Michaelis-Menten saturation kinetics). An understanding of these extensions will also serve you well in clinical pharmacology rotations and during drug development discussions in research settings.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A drug has a very large volume of distribution (Vd = 20,000 L). Does this mean the drug is physically present in 20,000 liters of body fluid? Explain what a high Vd actually indicates, and predict whether this drug is likely to be lipophilic or hydrophilic.

Show answer

No—Vd is an apparent volume, not a physical space. It represents the theoretical volume needed to contain the total drug at the measured plasma concentration. A Vd of 20,000 L greatly exceeds total body water (~42 L), indicating that the drug is extensively sequestered in tissues—binding to intracellular proteins, membranes, or fat stores—leaving very low plasma concentrations. This drug is almost certainly highly lipophilic, as lipophilic drugs readily cross membranes and accumulate in adipose tissue. Chloroquine is a classic example with a Vd exceeding 13,000 L, which is why hemodialysis is ineffective for chloroquine overdose.

Question 2: BASIC CALCULATION

Drug Y has a Vd of 40 L and a clearance of 8 L/hr. Calculate the half-life. If the drug is administered by continuous IV infusion, approximately how long will it take to reach steady-state concentration?

Show answer

Using the half-life equation: t_1/2 = (0.693 × Vd) / CL = (0.693 × 40) / 8 = 27.72 / 8 = 3.47 hours. Steady state is reached after approximately 4–5 half-lives: 5 × 3.47 = 17.3 hours. At that point, the rate of drug infusion equals the rate of elimination, and the plasma concentration plateaus. This calculation is independent of the infusion rate—changing the rate alters the steady-state level but not the time to reach it.

Question 3: INTERMEDIATE

A patient with normal renal function receives Drug Z at a maintenance dose of 200 mg every 8 hours orally (F = 0.75, CL = 10 L/hr). What is the average steady-state concentration (C_ss)? If the patient then develops renal failure and clearance drops to 5 L/hr, what should the new maintenance dose be to maintain the same C_ss?

Show answer

C_ss = (F × Dose) / (CL × τ) = (0.75 × 200 mg) / (10 L/hr × 8 hr) = 150 / 80 = 1.875 mg/L. When CL drops to 5 L/hr, to maintain the same C_ss: New Dose = C_ss × CL × τ / F = 1.875 × 5 × 8 / 0.75 = 100 mg every 8 hours. Since CL was halved, the dose is halved proportionally. Alternatively, the same dose could be given at double the interval (200 mg every 16 hours). The loading dose would remain unchanged because Vd is unaffected by renal failure.

Question 4: APPLIED

A 55-year-old man with cirrhosis is started on propranolol (a high hepatic extraction ratio drug) for variceal bleeding prophylaxis. His physician uses the standard oral dose. Why might this patient experience bradycardia and hypotension at doses that are well-tolerated in healthy individuals? Discuss at least two pharmacokinetic mechanisms contributing to this increased drug effect.

Show answer

Propranolol undergoes extensive first-pass hepatic metabolism (high extraction ratio). In cirrhosis, two key pharmacokinetic changes occur. First, reduced hepatic blood flow (due to portal hypertension and intrahepatic shunting) decreases hepatic clearance of high-extraction drugs, raising systemic drug levels. Second, portosystemic shunts divert blood around the liver, allowing more drug to bypass first-pass metabolism entirely, dramatically increasing bioavailability (F). Additionally, cirrhosis often reduces albumin production; since propranolol is highly protein-bound, decreased albumin increases the free (active) fraction. The combined effect of increased F, decreased CL, and increased free fraction leads to significantly higher active drug concentrations and the observed adverse effects.

Question 5: CRITICAL THINKING

A patient on phenytoin for seizures has a total plasma level of 8 μg/mL (therapeutic range: 10–20 μg/mL). The physician increases the daily dose from 300 mg to 350 mg, but the subsequent level jumps to 30 μg/mL with signs of toxicity (nystagmus, ataxia). Explain, using pharmacokinetic principles, why this modest 17% dose increase produced such a disproportionate rise in plasma concentration. How does this differ from what would happen with a drug that follows first-order kinetics?

Show answer

Phenytoin exhibits saturable (Michaelis-Menten) elimination kinetics within the therapeutic range, meaning its hepatic CYP2C9/CYP2C19 enzymes are operating near V_max. At 300 mg/day, the drug was near the inflection point on the Michaelis-Menten curve where clearance can no longer increase proportionally to drug input. The 50 mg/day increase pushed the rate of drug administration beyond the enzyme's maximum capacity, causing a shift from pseudo-first-order toward zero-order kinetics. Under zero-order conditions, plasma concentration rises non-linearly with dose—small increases produce disproportionately large concentration changes. In contrast, a drug following true first-order kinetics would have shown a proportional 17% increase in steady-state concentration (e.g., from 8 to ~9.4 μg/mL) because first-order clearance scales with concentration. This case illustrates why phenytoin requires careful titration with small increments and therapeutic drug monitoring, rather than the proportional dose adjustments safe for most other medications.

SUMMARY

Pharmacokinetics — Summary

Summary

Pharmacokinetics quantifies what the body does to a drug through four processes: Absorption (governed by bioavailability, F), Distribution (quantified by volume of distribution, Vd), Metabolism (Phase I CYP450 reactions and Phase II conjugation), and Excretion (measured by clearance, CL). The key relationships are: t₁/₂ = 0.693 × Vd / CL; Css = (F × Dose) / (CL × τ); and Loading Dose = Cp × Vd / F. Steady state is achieved after 4–5 half-lives.

Most drugs follow first-order kinetics (constant fraction eliminated per unit time, constant t₁/₂), while zero-order kinetics (constant amount per unit time, as seen with phenytoin, ethanol, and aspirin at saturation) poses toxicity risk because small dose changes cause disproportionate concentration increases. Clinical factors—renal failure, hepatic disease, CYP450 inducers/inhibitors, age, and protein binding—alter PK parameters and require dose adjustments. The critical distinction for dose modification: loading dose depends on Vd while maintenance dose depends on CL.